指南与共识肺栓塞与肺血管病

欧洲呼吸学会肺动脉高压治疗临床实践指南更新

European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension.
指南 / 共识 · Eur Respir J · 2026-09-07

欧洲呼吸学会工作组按GRADE方法更新肺动脉高压治疗指南,聚焦sotatercept及随访中右心导管作用。推荐已接受PAH药物且死亡风险中低、中高或高的患者加用sotatercept(高确定性证据);低风险患者因证据确定性低不作推荐。建议上述风险患者随访时行右心导管以指导治疗。

要点

  • 已用PAH药且死亡风险中低、中高或高的患者,推荐加用sotatercept(高确定性证据)。
  • 低风险患者因证据确定性低且RCT纳入少,不推荐sotatercept。
  • 中低、中高或高风险患者随访时建议行右心导管以指导治疗策略。

核心结论

  • 推荐已接受PAH药物且死亡风险中低、中高或高的患者加用sotatercept,基于随机对照试验的高确定性证据。
  • 低风险患者因证据确定性低且RCT纳入人数有限,工作组不作推荐。
  • 建议中低、中高或高风险患者随访时行右心导管,当预期有治疗后果时。

研究设计与样本

  • 欧洲呼吸学会工作组由全球专家、方法学家和患者代表组成,按ERS方法和GRADE方法制定。
  • 处理了四个PICO问题和一个个叙述性问题。

主要发现

  • sotatercept为靶向新通路的激活素信号抑制剂,指南聚焦其最新科学证据。
  • 指南同时聚焦右心导管在PAH患者随访管理中的作用。

关键数值与推荐

  • sotatercept推荐基于随机对照试验的高确定性证据。
  • 低风险患者不作sotatercept推荐,因证据确定性低且RCT纳入此类患者有限。
  • 右心导管推荐针对中低、中高或高风险患者,低风险患者因证据确定性极低不作推荐。

临床怎么用

  • 接受sotatercept的患者应在肺动脉高压中心治疗,管理包括定期随访和适当检查以监测安全性和疗效。
  • 随访中对中低、中高或高风险患者行右心导管以指导治疗策略。

局限性

  • 低风险患者因证据确定性低且RCT纳入人数有限,sotatercept不作推荐。
  • 低风险患者右心导管问题因证据确定性极低不作推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary arterial hypertension (PAH) is a severe, progressive disease of the small pulmonary arteries. These guidelines provide updated evidence-based recommendations for the treatment of PAH focusing on the latest scientific evidence on sotatercept, an activin signalling inhibitor targeting a novel pathway for the treatment of PAH, and on the role of right heart catheterisation (RHC) in the management of PAH patients during follow-up. METHODS: A European Respiratory Society (ERS) Task Force, comprising global experts, methodologists and a patient representative, developed these clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Four PICO (Patients, Intervention, Comparator, Outcomes) questions and one narrative question have been addressed. RECOMMENDATIONS: The Task Force recommends add-on treatment with sotatercept in PAH patients who already receive PAH drugs and are at intermediate-low, intermediate-high or high risk of death during follow-up; this recommendation is based on a high certainty of evidence available from randomised controlled trials (RCTs). In PAH patients at low risk of death, the Task Force does not provide a recommendation due to the low certainty of evidence and the limited number of such patients included in RCTs. To monitor safety and efficacy, patients receiving sotatercept should be treated in pulmonary hypertension centres and their management should include regular follow-up and appropriate examinations. To guide treatment strategy, the Task Force suggests performing RHC during follow-up in PAH patients who receive PAH drugs and are at intermediate-low, intermediate-high or high risk of death, when therapeutic consequences are expected. The Task Force does not provide a recommendation for this question in PAH patients at low risk of death, due to the very low certainty of evidence. CONCLUSION: The ERS guidelines on the treatment of PAH provide an updated evidence-based framework for the optimal management of patients with PAH.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Kovacs G, Zeder K, Humbert M, et al. European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension. Eur Respir J. 2026. PMID: 42705705. doi:10.1183/13993003.01178-2026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。